Aarti Pharmalabs Share Price

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas. It also provides contract development and manufacturing services for drug substance projects. Aarti Pharmalabs on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

The Aarti Pharmalabs stock price is influenced by various factors, such as its order book, capacity utilization, regulatory approvals from bodies like the USFDA, and global demand for pharmaceutical ingredients. In the longer run, strategies around backward integration, product diversification, and expansion into high-value molecules affect market sentiment. All these factors must be closely monitored to have an idea about the Aarti Pharmalabsstockprice movements.

Aarti Pharmalabslive share price provides real-time information about the lastAarti Pharmalabs stock pricetraded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Aarti Pharmalabslive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Aarti Pharmalabsshare͏price today helps investors understand real-time market sentiment,price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

AARTI PHARMALABS LIMITED COMPANY FUNDAMENTALS

a. Company Background

Aarti Pharmalabs Limited (APL), incorporated on August 23, 2019, is registered with its head office at 2nd Floor, 204, Udyog Kshetra, Mulund – Goregaon Link Rd, Mulund (W), Mumbai, Maharashtra, India. APL is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, New Chemical Entities (NCEs), and xanthine derivatives. The company integrates process chemistry expertise with scale-up engineering to support sustainable manufacturing. Over two decades, APL has evolved as a partner for both generic and innovative pharmaceutical companies, offering CDMO services across drug development stages from Phase I to commercial launch.

Its operations include production of high-potency APIs (HPAPIs), corticosteroids, cytotoxic medicines, and oncology drugs. APL’s flagship product, caffeine, is produced at India’s largest manufacturing capacity, supplying the pharmaceutical, nutraceutical, and beverage sectors worldwide. The company operates six manufacturing plants supported by two R&D centers, offering process R&D, scale-up, process optimization, and commercial manufacturing. Accreditations include USFDA, EU GMP, WHO-GMP, ISO 9001, ISO 14001, and ISO 45001, reflecting compliance with global regulatory standards. The company emphasizes sustainable growth, operational excellence, and innovation in its pharmaceutical and nutraceutical production.

b. Product Lines 

• Generic Active Pharmaceutical Ingredients (APIs)

• Pharmaceutical Intermediates

• New Chemical Entities (NCEs)

• Xanthine Derivatives

• Caffeine

• Acid & Allied Chemicals

• High-Potency APIs (HPAPIs)

• Corticosteroids

• Cytotoxic Medicines

• Oncology Products

• Regulatory Starting Materials (RSM)

• Key Building Blocks and Backward-Integrated Intermediates

• CDMO Services for drug substance/NCE development and manufacturing

c. Company Revenue Model 

• Sale of generic APIs and intermediates to pharmaceutical companies globally

• CDMO services for innovative pharma and biotech firms, covering Phase I–III, launch, and commercial stages

• Supply of xanthine derivatives and caffeine to pharmaceutical, nutraceutical, and beverage sectors

• Backward-integrated manufacturing ensures cost-efficiency and control over raw materials

• Export-focused revenue from regulated markets such as the USA, EU countries, and Japan

• Contract manufacturing for specialty APIs and NCEs

• Licensing and technology transfer arrangements with international partners

• Revenue diversification through both domestic sales and global exports

• Value-added services include stability studies, process validations, and scale-up optimization

d. Geographic Presence 

• Head Office: Mumbai, Maharashtra, India

• Manufacturing Sites:

• Unit-I: Dombivli, Maharashtra

• Unit-II: Vapi, Gujarat

• Units III–VI: Tarapur, Maharashtra

• Upcoming Greenfield Project: Atali, Gujarat

• Ports near manufacturing sites: Kandla, Nhava Sheva, Hazira, Dahej

• Domestic Presence: Supplies to pharmaceutical and nutraceutical companies across India

• International Exports: Products exported to regulated markets including the United States, European Union member countries, and Japan

• Global Partnerships: CDMO services offered to innovator pharma and biotech companies worldwide

• Industry Reach: Pharmaceutical, nutraceutical, and beverage sectors globally, leveraging backward-integrated production

e. Leadership

Some of the key leaders of Aarti Pharmalabs as of March 2026 are:

• Hetal Gogri Gala – Vice Chairman / Executive Director / MD

• Narendra Jagannath Salvi – Executive Director & MD

• Rashesh C Gogri – Chairman (Non-Executive) & Director (Non-Independent)

• Chandrakant V Gogri – Chairman Emeritus

• Jeevan Mondkar – Company Secretary, Compliance Officer, Head (Legal)

• Shri Sudhakar Shetty – Senior General Manager (HR & Admin.)

• Shri Piyush Lakhani – Chief Financial Officer

• Shri Ravindra Gurav – General Manager

• Shri Manoj Singh Bhadoria – General Manager

• Shri Dinesh Thokade – Deputy General Manager

f. Key Milestones

• 2019: Aarti Pharmalabs Limited incorporated

• 2020–2021: Expansion of manufacturing units in Tarapur and Vapi

• 2022: Greenfield project initiated at Atali, Gujarat

• 2023: USFDA, EU GMP, and WHO-GMP accreditations obtained

• 2024: Largest manufacturing capacity for caffeine in India achieved

• 2025: Strengthened global exports to USA, EU, and Japan; CDMO partnerships expanded

g. Industry Perspective

The global pharmaceutical active ingredients and intermediates industry, part of the broader pharmaceutical chemicals and contract development and manufacturing organization (CDMO) sector, underpins drug production by supplying essential chemical compounds used in finished medications. The active pharmaceutical ingredients (API) segment forms a critical part of this industry; the global API market was valued at approximately USD 315.7 billion in 2025 and is projected to approach USD 600.7 billion by 2034, implying a CAGR of around 7.3 % over the period. India’s API market alone was estimated at USD 13.03 billion in 2023 and is forecast to reach USD 37.11 billion by 2032, growing at a CAGR of about 12.33 % (2024–2032), reflecting strong domestic manufacturing and export demand. The pharmaceutical intermediates segment — chemicals used to synthesise APIs — was valued around USD 15.7 billion in 2025 and is expected to grow at a CAGR of ~7.25 % to USD 27.5 billion by 2032. Within India, API market forecasts indicate growth rates of 7–7.7 % through the late 2020s, driven by rising chronic disease prevalence, biopharma innovation, and increasing contract manufacturing demand from regulated markets like the USA and EU

Aarti Pharmalabs Stock Market Presence: Listings & Index Representation

Aarti Pharmalabs Limited was listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) on October 11, 2021, following the demerger of the pharma and chemical business from its erstwhile parent company, Aarti Industries Limited.

Aarti Pharmalabs Limited is a prominent entity in the Indian stock market, listed on major exchanges with the NSE symbol AARTIPHARM and BSE scrip code 543718. Its inclusion in prominent indices like the S&P BSE Healthcare, BSE 1000, Nifty Microcap 250 Index, Nifty Total Market, S&P BSE MidSmallCap, S&P BSE SmallCap, and S&P BSE AllCap underscores the company’s significance in India’s pharmaceutical and specialty chemicals sector.

Aarti Pharmalabs stock price is closely tracked by retail and institutional investors. Its inclusion in these major indices reflects strong market capitalization, its niche in the API manufacturing space, and its scale in both domestic and regulated markets. Listing on NSE and BSE ensures liquidity, while its presence in these indices drives institutional holdings and benchmark tracking within the healthcare sector.

Aasrti Pharmalabs Stock Performance and Aarti Pharmalabs Share Price History

Aarti Pharmalabs share price on NSE and BSE reflects its standing as a key manufacturer in the API and specialty chemicals space. Performance is driven by order inflows, capacity expansions, raw material prices, and regulatory clearances. Investors compare Aarti Pharmalabs share price today with the Nifty Pharma index and peer companies to gauge relative performance.

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Aarti Pharmalabs share price. In addition to operational factors, corporate actions such as the company’s demerger from Aarti Industries have had a significant impact on Aarti Pharmalabs share price movements, establishing a new price discovery phase. This shows how such events can trigger short-term swings.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Aarti Pharmalabs share price 52-week high and low. The 52-week high of ₹971 and low of ₹574.45 provide context beyond daily changes. Highs indicate strong demand and capacity utilization, while lows align with market corrections or sector-specific volatility.

Aarti Pharmalabs stock performance reflects the trading behaviour of a company operating within the highly regulated pharmaceutical industry. Its focus on complex chemistry and diversified product portfolio has shaped its Aarti Pharmalabs share price history. Since its listing, the stock has shown strong wealth creation, marked by periods of sharp gains and phases of consolidation.

The period from 2023 to 2024 witnessed strong growth for Aarti Pharmalabs share price. The stock delivered returns of 73.79% in 2023 and 35.91% in 2024. This growth was driven by increased demand for APIs, successful capacity expansions, and improved operational efficiencies. Conversely, a significant decline was observed in 2025, with the Aarti Pharmalabs share price falling by 9.36% for the year, and further weakness extending into 2026.

Aarti Pharmalabs stock performance over time has closely followed the industry’s cycles. For instance, the Aarti Pharmalabs share price reached an all-time high above ₹971 in June 2025, supported by strong investor confidence and stable business fundamentals. Over longer investment horizons, the stock has delivered mixed returns, with a notable 124.09% gain over three years, but a decline of 14.22% over five years, showcasing the volatility inherent in the sector.

Despite broader market challenges, Aarti Pharmalabs shares remained resilient in certain periods. While the sector faced margin pressure from volatile raw material costs, the company’s focus on backward integration helped manage costs and retain value. However, in the first quarter of 2026, the Aarti Pharmalabs share price declined by -14.7%, reflecting a combination of broader market corrections and sector-specific headwinds that impacted investor sentiment.

Aarti Pharmalabs Investor Relevance and Role in Portfolio

Aarti Pharmalabs is considered a key player in the mid-cap pharmaceutical space, offering exposure to the API and specialty chemicals segment. Its inclusion in indices like the Nifty Microcap 250 and S&P BSE SmallCap underscores its importance. Strong focus on R&D, a diversified product mix, and regulatory compliance make it a relevant choice for thematic portfolios focused on manufacturing and healthcare.

Aarti Pharmalabs equity is held by a broad mix of leading domestic and international institutional investors, reflecting its prominence in India’s pharmaceutical sector. Top institutional stakeholders include Life Insurance Corporation of India, Anushakti Enterprise Private Limited, quant Money Managers Ltd., Labdhi Business Trust, The Vanguard Group, Inc., NTAsset (Cayman) Limited, NTAsian Discovery Master Fund, Barclays Bank PLC, Relacion Trusteeship Services Private Limited, and Alabhya Trusteeship Private Limited.

Prominent mutual fund holders include Vanguard STAR Funds – Vanguard Total International Stock ETF, iShares, Inc. – iShares Core MSCI Emerging Markets ETF, Vanguard International Equity Index Funds – Vanguard FTSE Emerging Markets ETF, Vanguard Fiduciary Trust Company Institutional Total International Stock Market Index Trust II, DFA Investment Dimensions Group Inc. – Emerging Markets Core Equity 2 Portfolio, Vanguard International Equity Index Funds – Vanguard FTSE All-World ex-US Small-Cap ETF, Motilal Oswal Amc Ltd. – Motilal Oswal Mutual Fund – Motilal Oswal Nifty Microcap 250 Index Fund, iShares Public Limited Company – iShares Core MSCI EM IMI UCITS ETF, and Hdfc Mutual Fund – Hdfc Multi Cap Fund.

Beyond fundamentals, Aarti Pharmalabs stock is monitored in derivatives markets, where open interest and rollover patterns reflect expectations on order book growth, margins, and regulatory news. Technical indicators such as Aarti Pharmalabs RSI, MACD, and MFI provide additional insight into short-term momentum shifts in Aarti Pharmalabs stock price. While primarily used for near-term trading, these tools can help gauge market sentiment and potential volatility around major events.

Aarti Pharmalabs’ beta has varied across different time frames, reflecting its nature as a mid-cap pharmaceutical stock. The long-term beta is 0, while the daily beta over a one-month range is 1.01, and over a three-month range is 0.901. Over a weekly one-year range, the beta is higher at 1.41, showing higher correlation with market movements during that period. The weekly two-year beta is 0.859, the two-week two-year beta is 1.10, and the monthly two-year beta is 0.468. These figures highlight that the stock’s volatility relative to the market can shift significantly depending on the time frame, with higher beta in the short term suggesting more pronounced swings compared to broader indices.

Aarti Pharmalabs Sectoral Relevance and Peer Positioning

Aarti Pharmalabs’ sector relevance stems from its expertise in complex API synthesis and specialty chemicals, establishing it as a key mid-cap player supporting India’s pharmaceutical ecosystem. Peer comparisons with companies like Divi’s Laboratories, Laurus Labs, Neuland Laboratories, Granules India, and Suven Pharmaceuticals focus on product portfolio complexity, regulatory compliance, R&D capabilities, and capacity expansion rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and global competitiveness. Institutional tracking of API demand trends, pricing power, and export growth further highlights Aarti Pharmalabs’ positioning within India’s broader pharmaceutical market.

Aarti Pharmalabs’ market cap has shown significant growth since its listing. From January 30, 2023, to March 24, 2026, the market cap increased from ₹26.12B to ₹57.93B, a growth of 121.76% representing a CAGR of 28.79%. Year-end values highlight this trajectory: ₹45.72B at the end of 2023, ₹62.19B at the end of 2024, and ₹68.20B at the end of 2025. This growth was driven by strong business performance and investor confidence. However, the market cap saw a decline to ₹56.46B by March 24, 2026, a 17.22% drop from the 2025 year-end high, reflecting recent market volatility and sectoral pressures.

Aarti Pharmalabs’ earnings trend shows an overall upward trajectory with some fluctuations. Revenue stood at ₹12.00B in fiscal year 2022. It saw a substantial jump of 62.11% to ₹19.45B in fiscal year 2023. A slight decrease of 4.76% occurred in fiscal year 2024, with revenue at ₹18.53B. The company rebounded in fiscal year 2025, reporting a revenue of ₹21.15B, an increase of 14.17% from the previous year. The trailing twelve months revenue as of March 24, 2026, was ₹18.01B, with a revenue growth of -12.47% compared to the previous fiscal year-end.

Aarti Pharmalabs’ EPS (earnings per share) on a consolidated basis has shown varied performance. In fiscal year 2021, the EPS was at a negative -₹0.18. The following year, fiscal 2022, saw a sharp positive spike to ₹4,890.04, likely due to one-time demerger-related adjustments. Normalizing after the demerger, EPS was ₹21.35 in fiscal 2023. It then grew by 12.08% to ₹23.93 in fiscal 2024. This positive trend continued, with EPS increasing by 25.62% to ₹30.06 in fiscal year 2025. This steady growth in recent years indicates improving profitability from the core operations of the API and specialty chemicals business.

Aarti Pharmalabs P/E ratio provides insight into its market valuation. The P/E ratio has been trending up, rising from 12.92 in fiscal year 2023 to 18.18 in fiscal year 2024, a 40.68% increase. It continued to rise by 37.13% in fiscal year 2025 to reach 24.93. The current trailing twelve months P/E ratio as of March 24, 2026, is 27.12. This P/E ratio of 27.10 (the latest reported) suggests the stock price is high compared to company earnings. The current ratio is also greater than the average P/E of 11.20 observed over the last five years, reflecting a period of increased investor interest and premium valuation.

Summary

Aarti Pharmalabs Limited is a key manufacturer in the Indian API and specialty chemicals sector, with a strong operational base in Mumbai. The company’s stock is listed on the NSE and BSE and is part of several key indices. Aarti Pharmalabs share price performance has seen significant growth phases, particularly in 2023 and 2024, followed by recent corrections. The company’s financial metrics, including revenue and EPS, show a steady improvement in recent fiscal years.